Share This Page
Litigation Details for Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc. (D. Del. 2024)
✉ Email this page to a colleague
Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc. (D. Del. 2024)
| Docket | 1:24-cv-01192 | Date Filed | 2024-10-24 |
| Court | District Court, D. Delaware | Date Terminated | 2025-03-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Patents | 10,105,323; 9,907,756 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc.
Details for Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc. (D. Del. 2024)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-10-24 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation summary and analysis for: Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc. (D. Del. 2024)
Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc. (1:24-cv-01192) | Litigation Summary, Patent Issues, and Likely Outcome Drivers
Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc., No. 1:24-cv-01192, is a Hatch-Waxman patent infringement dispute tied to a generics pathway against Boehringer Ingelheim’s branded product. The key determinants of the case outcome are (1) whether Sandoz asserts non-infringement and/or invalidity for specific Orange Book-listed patents, (2) the asserted patent categories (composition, formulation, method-of-use, or manufacturing), (3) the court’s Markman claim-construction positions, and (4) the availability of statutory triggers that control launch timing (expiration, exclusivity, and any stay from FDA “42 U.S.C. § 355(j)” automatic stay rules).
No litigation docket text, complaint allegations, asserted patents, or orders were provided in the prompt, so a patent-by-patent infringement/validity and timeline analysis cannot be produced from reliable primary records.
What patents are at issue in Sandoz v. Boehringer (1:24-cv-01192)?
A proper litigation summary requires the specific asserted Orange Book patents and the allegations pleaded in the complaint (claims identified, theories of non-infringement, and invalidity grounds). Those details are not included in the input.
Which Orange Book patents drive the case?
Featured-snippet level answer: the litigation is likely tied to one or more Boehringer Ingelheim patents listed in the Orange Book for the reference listed drug implicated by Sandoz’s ANDA, but the asserted patent numbers are not available from the provided data.
How many patents are typically asserted in cases at this docket stage?
Cases filed in this posture often involve multiple patent families (drug substance and/or formulation and/or use), but the number cannot be stated without docket contents.
What claims does Sandoz challenge: composition, formulation, or method of use?
A credible analysis requires the claim chart elements cited in the infringement contentions and the patent categories actually asserted.
Composition-of-matter vs. method-of-use
If composition-of-matter patents are asserted, Sandoz’s common defenses are non-infringement based on structural or compositional differences and invalidity under §§ 102/103/112.
If method-of-use patents are asserted, typical disputes focus on label, prescribing instructions, and whether the proposed ANDA product is “used for” the claimed method in a way that constitutes inducement or direct infringement under the Hatch-Waxman framework.
The case-specific category cannot be mapped without the complaint or the court’s scheduling order.
When does Boehringer’s exclusivity or patent protection expire for the implicated product?
Exclusivity timing is usually the main commercial risk driver after a counterparty files an infringement suit. Determining “when it loses exclusivity” requires:
- the reference product’s Orange Book entries,
- the exclusivity type (NCE, 3-year, 7-year, pediatric, orphan, etc.),
- and the patent expiration dates and any pediatric exclusivity extensions.
No Orange Book listing or Boehringer product identification is included in the prompt, so no exclusivity expiration date can be stated.
What is the Orange Book status of the Boehringer Ingelheim product in 1:24-cv-01192?
Orange Book status analysis depends on:
- the RLD name,
- ANDA reference,
- listed patents by submission number,
- the listed expiration dates,
- and the exclusivity flags.
Those items are not provided, so this section cannot be completed.
How does Markman claim construction likely affect Sandoz v. Boehringer?
Markman construction is often decisive in patent infringement disputes because it governs:
- the meaning of key functional limitations,
- whether the generics product design-around avoids infringement,
- and how invalidity theories apply to the narrowed claim language.
But the court’s construed terms, disputed claim limitations, and claim-construction schedule are not available from the prompt, so no case-specific analysis can be provided.
What procedural milestones matter most in Hatch-Waxman cases like this?
For a high-confidence litigation summary, you need the docket milestones such as:
- complaint and answer dates,
- early motions (dismissal/transfer/stay),
- claim construction schedule,
- expert submission dates,
- summary judgment filings,
- trial date or dispositive order outcomes.
None of these dates are provided in the input.
How strong is Boehringer’s patent estate based on typical court outcomes?
A “strength” assessment requires:
- asserted patent classes,
- prior art landscape,
- prosecution history,
- and how courts have treated similar families.
Without asserted patent numbers and claims, no strength rating can be made.
What Paragraph IV challenges did Sandoz file, and what does that imply about design-around and invalidity?
Paragraph IV theories usually fall into two tracks:
- non-infringement: the ANDA product does not meet one or more claim limitations as construed;
- invalidity: the asserted patents fail statutory requirements (novelty, obviousness, enablement, written description, indefiniteness).
To analyze the actual Paragraph IV basis, the ANDA certification(s) and the specific patents challenged must be identified. Those are not in the prompt.
What generic entry risks exist for Sandoz if Sandoz loses on infringement?
This depends on:
- whether any asserted patents are upheld,
- whether injunctions are stayed pending appeal,
- and the remaining expiration/exclusivity window.
Because the asserted-patent list is unknown, the launch risk level cannot be calculated.
What generic launch timing outcomes could follow settlement or final judgment?
Settlement and consent judgment outcomes are driven by:
- which patents are resolved,
- the agreed-upon “design-around” or modified launch date,
- and whether any stipulated entry date is later than the earliest patent expiration.
No settlement terms or any court orders are provided.
Which court rulings typically control launch in Sandoz-type disputes?
Launch timing is typically controlled by:
- whether the court grants a permanent injunction for infringement,
- whether a preliminary injunction is granted (rare but possible),
- whether claims are held invalid,
- and any “section 355(j)(5)(B)” stay mechanics tied to the filing and adjudication timeline.
No such rulings are listed in the prompt.
How does Sandoz v. Boehringer compare with other 2024 Sandoz Hatch-Waxman disputes?
A comparison requires identifying:
- the referenced RLD,
- asserted patent families,
- defendants and outcomes,
- and whether settlements occurred with date-certain entry.
No comparative case list or drug identity is included.
Revenue exposure: how much is at stake for Sandoz or Boehringer from this litigation?
Revenue exposure depends on:
- the sales of the reference product (brand revenue or branded revenue tied to the RLD),
- the expected ANDA market penetration,
- and the likelihood and timing of launch.
No implicated product or sales data is included.
Key Takeaways
- Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc., No. 1:24-cv-01192, is positioned as a Hatch-Waxman patent infringement dispute, but the prompt provides no docket allegations, asserted patent numbers, claim constructions, or orders.
- Case outcome and generic launch timing hinge on which Orange Book-listed patents are asserted, the claim construction, and the court’s rulings on infringement/invalidity, but those specifics are not available in the input.
- A patent-by-patent litigation summary and expiration/exclusivity timeline cannot be produced from the provided information alone.
FAQs
- What is the usual standard for claiming non-infringement in ANDA/Hatch-Waxman cases?
- How does claim construction typically influence whether a generic can design around a formulation or method-of-use claim?
- What happens to ANDA approval timing if a court grants or denies summary judgment on infringement?
- What are the most common invalidity grounds asserted for Orange Book-listed patents in Paragraph IV cases?
- When do settlements in Hatch-Waxman disputes typically create date-certain entry schedules, and what terms drive them?
References (APA)
- U.S. District Court, District of New Jersey. Sandoz Inc. v. Boehringer Ingelheim Pharmaceuticals Inc., No. 1:24-cv-01192. (Docket details not provided in input).
More… ↓
